Alector, Inc. Files Q1 2025 10-Q

Ticker: ALEC · Form: 10-Q · Filed: May 8, 2025 · CIK: 1653087

Alector, INC. 10-Q Filing Summary
FieldDetail
CompanyAlector, INC. (ALEC)
Form Type10-Q
Filed DateMay 8, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, financials, biotechnology

TL;DR

Alector's Q1 2025 10-Q is in. Check financials.

AI Summary

Alector, Inc. filed its 10-Q for the period ending March 31, 2025. The company, focused on biological products, reported on its financial activities. Key financial data points and disclosures related to its operations and financial instruments are included in this filing.

Why It Matters

This filing provides investors and analysts with a quarterly update on Alector's financial health and operational performance, crucial for understanding the company's trajectory in the biotechnology sector.

Risk Assessment

Risk Level: medium — Biotechnology companies often face high risks due to the nature of drug development, clinical trials, and regulatory approvals, which can significantly impact financial performance.

Key Players & Entities

FAQ

What is the reporting period for this 10-Q filing?

The Conformed Period of Report is 20250331, indicating the filing covers the first quarter of 2025.

When was this 10-Q filed with the SEC?

This 10-Q was filed on 20250508.

What is Alector, Inc.'s Standard Industrial Classification code?

Alector, Inc.'s SIC code is 2836, categorized under Biological Products (No Diagnostic Substances).

What is the business address of Alector, Inc.?

Alector, Inc.'s business address is 131 Oyster Point Blvd., Suite 600, South San Francisco, CA 94080.

Are there any specific financial instruments or agreements mentioned with dates?

Yes, the filing references 'CashPledgedAgreementMember' as of 2024-12-31 and 'GskMember' on 2021-08-17, among other date-specific financial disclosures.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Alector, Inc. (ALEC).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing